
Your Feed
KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24
KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24
MRD Status in Myeloma: Insights on Changes During Maintenance | Ross Firestone, MD, PhD | #ASH24
MRD Status in Myeloma: Insights on Changes During Maintenance | Ross Firestone, MD, PhD | #ASH24
CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24
CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24
Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24
Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24
Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD | #ASH24
Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD | #ASH24
Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD| #ASH24
Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24
Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24
Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24
Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24
Talquetamab Efficacy & Toxicity in African American Myeloma Patients | Carolina Schinke, MD | #ASH24

